Impact of Hemodialysis on Plasma Carnitine Levels in Patients With End Stage Renal Disease - Trial NCT05817799
Access comprehensive clinical trial information for NCT05817799 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Bahria University and is currently Recruiting. The study focuses on Hemodialysis Complication. Target enrollment is 83 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Bahria University
Timeline & Enrollment
Phase 2/3
Jan 01, 2023
Jul 10, 2023
Primary Outcome
L-Carnitine levels in hemodialysis
Summary
OBJECTIVES
 
 - To assess the levels of plasma carnitine in controls and hemodialysis patients.
 
 - To give supplementary L-carnitine to study subjects for a duration of 5months.
 
 - To compare the values of plasma carnitine before and after L carnitine supplementation.
 
 - To assess the role of carnitine supplementation on biochemical and clinical parameters.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05817799
Non-Device Trial